Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03145129
Other study ID # P02145
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 24, 2017
Est. completion date February 10, 2018

Study information

Verified date June 2018
Source Papworth Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Some people with Primary Open-angle Glaucoma (POAG) also suffer from Obstructive Sleep Apnoea (OSA), a common sleep disorder which is known to affect heart and blood vessels, and may contribute to glaucoma progression. Obstructive Sleep Apnoea is treated with Continuous Positive Airway Pressure (CPAP)Íž however using this type of breathing support may raise intraocular pressure (IOP). The evidence for this is limited and the potential mechanisms involved are poorly understood.

In this study we will determine whether CPAP applied at night changes IOP and ocular perfusion pressure (OPP). We will also assess its possible impact on ocular microvasculature. Two groups of patients will be included: those with POAG and OSA, and those with OSA without glaucoma. They will attend for two overnight assessments: the first before starting CPAP and the second 4-6 weeks into the treatment. Repeated measurements of IOP at night will be performed and participants will continue self-measuring IOP at home in the day. An Ocular Coherence Tomography Angiography (OCT Angiography) of the optic disc and the surrounding retina will be performed at baseline and after a few weeks of CPAP treatment.


Description:

People with OAG and concomitant OSA associated with the relevant symptoms, particularly daytime sleepiness, currently receive standard treatment with CPAP. However, the impact of CPAP on their glaucoma is unknown. There are concerns that CPAP increases IOP, currently the only modifiable factor in glaucoma, though the evidence for this is limited.

Understanding the influence of CPAP on IOP is important as it may inform the management of people with OSA and concomitant glaucoma. If CPAP is shown to raise IOP or alter OPP to levels that pose clinical risk it will be necessary to assess available alternative treatment options for OSA. If, however, CPAP does not alter these parameters, there would be a rationale for assessing long-term effects of CPAP, most probably in the form of a randomised interventional trial, informed by the findings of this research.

This is a prospective controlled study which will examine the impact of CPAP on nocturnal IOP and OPP in people with OSA with and without POAG. In addition, we will assess ocular microvasculature before and a few weeks into CPAP treatment.

Objectives:

Primary: to determine if IOP increases at night following treatment with CPAP in people with OSA with and without POAG.

Main Secondary:(i) to investigate whether diurnal IOP raises after CPAP treatment; (ii) to investigate whether CPAP alters peri-papillary and macular microcirculation measured with OCT Angiography.

Participants: People with newly diagnosed OSA who require treatment with CPAP will be invited. We will recruit participants with POAG and people without glaucoma (control subjects). All participant will undergo a detailed ocular assessment including: visual acuity, IOP measurement, OCT and visual field test.

Sample Size: 30 participants: 15 per group.

Study Visits:

Visit 0: Baseline ocular examination to confirm or exclude glaucoma will be undertaken during this visit unless a participant already had this examination within the last 6 months.

Visit 1: Participants will attend the sleep centre (Respiratory Support and Sleep Centre-RSSC, Papworth Hospital) where they will be admitted to a separate ward. Consented participants will undergo the following:

Baseline assessment: A brief medical history, spirometry and anthropomorphic measurements.

Repeated measurements: IOP will be measured in each eye using a rebound tonometer (Icare Pro, Finland Oy). Blood pressure and ocular perfusion pressure will be checked simultaneously.

Participants will be advised to sleep at their habitual hours. Sleep onset and duration will be recorded. All the above measurements will be repeated every 2 hours starting from 10pm and finishing at 8am. In the morning OCT Angiographic will be performed.

Participants will then self-measure IOP at home using a rebound tonometer (Icare Home, Finland Oy). The measurements will be performed in the daytime every 2 hours before they start CPAP and 4-6 weeks into the treatment.

Visit 2: Participants will return for the second overnight assessment 4-6weeks after initiation of CPAP treatment.

CPAP usage data will be downloaded. All the measurements following the same procedure as for Visit 1 will be repeated this time with participants using CPAP. OCT Angiographic will be performed immediately after removing CPAP in the morning.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date February 10, 2018
Est. primary completion date February 10, 2018
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Newly diagnosed, untreated OSA with indications for CPAP

- Age >40 years

- Able to give informed consent and attend for the study visits.

Exclusion Criteria:

- Known or suspected pregnancy

- Any contraindications to rebound tonometry, including: corneal scarring, microphtalmos, buphthalmos, nystagmus, keratoconus, abnormal central corneal thickness, corneal ectasia, , active corneal infection, , and corneal dystrophies

- Eye diseases known to affect IOP, including: treated wet age related macular degeneration (ARMD), central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), uveitis and diabetic retinopathy.

- Indications to start CPAP treatment urgently unless the study visits can be organised in a way there is no delay in treatment initiation.

- Irregular sleep pattern

- Insomnia

- Acute infectious diseases

- Inability to undergo screening ophthalmic examination

Study Design


Intervention

Device:
Continuous Positive Airway Pressure
Continuous Positive Airway Pressure

Locations

Country Name City State
United Kingdom Papworth Hospital Cambridge

Sponsors (2)

Lead Sponsor Collaborator
Papworth Hospital NHS Foundation Trust Hinchingbrooke Healthcare NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraocular pressure (IOP) Difference between baseline IOP at night and nocturnal IOP on CPAP On completion of study visit 2: 6 weeks
Secondary Diurnal IOP change A difference in diurnal IOP self-measured at home at baseline and during CPAP treatment. On completion of study visit 2: 6 weeks
Secondary Differences in change in IOP between the study group Differences in IOP change (?IOP; IOPCPAP -IOPbaseline) between the groups On completion of study visit 2: 6 weeks
Secondary Relationship between change in IOP on CPAP with OSA severity Correlation between IOP change (?IOP) and AHI (Apnoea-Hypopnoea Index) On completion of study visit 2: 6 weeks
Secondary Relationship between change in IOP on CPAP with POAG severity Correlation between IOP change (?IOP) and VFI (Visual Field Index) On completion of study visit 2: 6 weeks
Secondary Ocular Perfusion Pressure (OPP) Difference between baseline OPP at night and nocturnal OPP on CPAP in each group On completion of study visit 2: 6 weeks
Secondary Optic disc vessel density Optic disc vessel density at baseline and after 4-6 weeks of CPAP treatment On completion of study visit 2: 6 weeks
Secondary Peripapillary vessel density Peripapillary vessel density at baseline and after 4-6 weeks of CPAP treatment On completion of study visit 2: 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT01841437 - Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry N/A
Completed NCT01410188 - Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension Phase 1/Phase 2
Completed NCT02077231 - Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients N/A
Recruiting NCT05557058 - GORE Glaucoma Drainage Implant Clinical Study N/A
Not yet recruiting NCT03924544 - Decorin in Sub Scleral Trabeculectomy Phase 1
Active, not recruiting NCT03673644 - Impact of Glaucoma and Visual Field Loss on Life Space
Completed NCT03365778 - Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment N/A
Completed NCT01915940 - Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Phase 2
Completed NCT03889652 - Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
Terminated NCT03273907 - Post Approval Study of the CyPass System N/A
Recruiting NCT03193333 - PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) Phase 3
Recruiting NCT03921931 - Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study N/A
Not yet recruiting NCT04609345 - Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
Recruiting NCT05264818 - Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
Completed NCT04333433 - PRESERFLO® MicroShunt Extension Study
Enrolling by invitation NCT02144103 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Phase 1/Phase 2
Completed NCT01281020 - Adherence With Fixed Versus Unfixed Glaucoma Therapy
Recruiting NCT04891588 - Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD N/A
Completed NCT03104621 - Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Phase 4
Completed NCT01528111 - Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Phase 1/Phase 2